IL-22 Agonists for Intestinal Barrier Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for microbial disorders, such as Inflammatory Bowel Disease (IBD), lack effective methods to modulate the host immune response against attaching and effacing bacterial pathogens, which can lead to severe infections and complications.
Innovation Solution
The use of IL-22 polypeptides or IL-22 agonists, including IL-22-Fc fusion polypeptides, nucleic acids, fusion polypeptides, antibodies, or humanized antibodies that bind to IL-22, IL-22R, or IL-22BP, to enhance the host's immune response and treat microbial disorders by increasing IL-22 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for microbial disorders are used, then existing therapeutic options are available, but they lack effective methods to modulate the host immune response against attaching and effacing bacterial pathogens
Solution Approach 1:
The patent changes the parameter of immune response modulation by introducing IL-22 and its agonists, which specifically enhance the host's immune response against attaching and effacing bacterial pathogens. This resolves the contradiction by providing a targeted immunomodulatory approach that improves treatment effectiveness while adapting to the specific pathogen mechanism
Solution Approach 2:
The patent uses IL-22 as an intermediary substance that mediates between the host immune system and the bacterial pathogen. IL-22 acts as a cytokine that enhances epithelial cell function and immune response, serving as a bridge that improves treatment effectiveness without directly attacking the pathogen, thus resolving the contradiction between reliability and adaptability
2Reliability
If IL-22 or its agonists are administered to enhance immune response, then protection of intestinal epithelial barrier and prevention of bacterial invasion is improved, but the complexity of treatment options increases
Solution Approach 1:
The patent applies universality by using IL-22 as a multi-functional agent that simultaneously protects the intestinal epithelial barrier, prevents bacterial invasion, and modulates immune response. This single agent addresses multiple therapeutic needs, resolving the contradiction between improved reliability and treatment complexity
Solution Approach 2:
The patent employs preliminary action by administering IL-22 or its agonists before severe infection sets in, or at the early stages of infection, to prevent bacterial invasion and enhance the host's defensive capabilities. This proactive approach improves barrier protection while maintaining relatively simple treatment protocols
Data Source
Figure 1A~1H
Figure 2A~2F
Figure 3A~3G
AI summary
The present invention relates to compositions and methods for treatment of microbial disorder by modulation of the host immune response. More particularly, the present invention relates to compositions that mediate an anti-microbial immune response, and methods of treating a microbial infection using such compositions.